The company leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. ATAI is committed to acquiring and efficiently developing innovative treatments that lead to paradigm shifts in the mental health space. They have a clinical-stage biopharmaceutical product pipeline that includes COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. ATAI operates in the United States and Germany and aims to heal mental health disorders so that everyone, everywhere can live a more fulfilled life by pooling expertise, best practices, and resources across their entire portfolio.